- Home
- LASE vs NRXP Comparison
LASE vs NRXP Comparison
Compare LASE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LASE | NRXP |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 62.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LASE | NRXP |
|---|---|---|
| Price | $0.96 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | ★ 3.1M | 516.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $721,185.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $1.58 |
| 52 Week High | $6.77 | $3.84 |
Technical Indicators
Market Signals| Indicator | LASE | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 42.16 |
| Support Level | $0.38 | $1.65 |
| Resistance Level | $2.54 | $2.79 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 50.72 | 36.21 |
Price Performance
Historical ComparisonAbout LASE Laser Photonics Corporation
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasives blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, aerospace, machine manufacturing, nuclear maintenance and de-commissioning, and surface coating.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.